Edwards Acquisition of JenaValve Called Off

January 12, 2026—Edwards Lifesciences announced that it will not be acquiring JenaValve Technology, a developer of transcatheter treatments for aortic regurgitation (AR).

According to Edwards, the decision follows the US District Court for the District of Columbia’s grant of a motion by the Federal Trade Commission (FTC) for an injunction blocking the proposed acquisition of JenaValve, which was first announced in July 2024. In August 2025, the FTC advised it had moved to block the transaction.

In its press release, Edwards stated that it disagrees with the decision and believes that the acquisition would have been in the best interest of patients with AR.

The company further advised it remains committed to AR therapy, including advancing the Sojourn transcatheter AR valve and enrolling patients in the JOURNEY pivotal trial.